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Abstract
Cisplatin is one of the most widely used anti-cancer drugs. Its primary
cellular target is genomic DNA to which it binds predominantly by forming
an intra-strand crosslink between two adjacent purine bases. This
bifunctional binding is thought to occur via initial formation of a
monofunctional adduct followed by closure in the 5’ or 3’ direction.
Experimental evidence suggests that the 5’ direction is exclusively
preferred. This study focuses on understanding this directional preference
using high-level DFT models. Fully optimized bifunctional structures for
the dinucleotides 5’dApG3’ (AG) and 5’dGpA3’ (GA) bound to cisplatin
reveal that the AG adduct is lower in energy than GA by around 7
kcal/mol. The underlying electronic features that give rise to this
thermodynamic difference of platinum binding were examined in detail.
Surprisingly, we found that the puckering of the ribose rings plays an
important role in determining the energetics of the bifunctional adducts.
Introduction
Cis-diamminedichloroplatinum(II) (Fig 1, left), cisplatin, is a potent anti-cancer
drug which is widely used against a variety of cancers, in particular testicular cancer.2
Although it was approved for use by the FDA in 1978, and is one of the most successful
anti-cancer drugs, its use has been limited due to its severe side-effects.2 Several other
platinum-based drugs have been tested, but only a few among them have been approved
for clinical use to date, namely carboplatin30 and oxaliplatin29. Despite its widespread
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usage, many aspects of the cytotoxic mechanism of cisplatin are not fully understood. A
better understanding of its cellular binding behavior and its effect on cell-survival may help
in the rational design of better platinum-based drugs.
The anti-tumor activity of cisplatin was discovered accidentally during a study of
the effect of an electric field on bacterial growth.3 Compounds formed by the reaction of
the platinum electrodes with the ammonium chloride in the buffer stopped cell division and
induced filamentous growth.3 These compounds were later tested on mice and found to
exhibit anti-tumor activity, which eventually lead to the FDA approval of cisplatin.
Cisplatin contains two labile chloride ligands in the cis position that function as
leaving groups (Fig 1, left).4 These ligands remain bound to platinum in the plasma due to
its high chloride concentration of around 100 mM. Once inside a cell, however, the
sharply decreased intracellular chloride concentration of around 4 mM5 causes cisplatin to
undergo hydrolysis, wherein the chloride ligands are substituted by aqua ligands to form
the activated complexes [Pt(NH3)2Cl(H2O)]+ and [Pt(NH3)2(H2O)2]2+ (Fig 1, right). These
complexes then bind to various cellular components like DNA, RNA, proteins and
membrane phospholipids.
Cl
Cl
Pt
NH3
NH3
Cl
Cl
Pt
NH3
NH3
Cl
OH2
Pt
NH3
NH3OH2 Cl+ +
+
372
Cl
OH2
Pt
NH3
NH3
ClPt
NH3
NH3 OH2G
G
+ +
++
Major targets for cisplatin and common binding modes
Although there are several intracellular targets for cisplatin, the major target is
genomic DNA.6, 7 Specifically, the N7 of purine bases is the main binding site, with
guanine being preferred over adenine by approximately 5 kcal/mol.8 The possible binding
modes include monofuntional and bifunctional binding to a single guanine base, intra and
interstrand bifunctional binding, and DNA-protein crosslinking (Fig 2).28 Due to the cis
orientation of the leaving groups, bifunctional binding to two adjacent bases is most
preferred, with GpG9 adducts forming the majority of adducts followed by ApG10, 11
adducts. Surprisingly, the GpA adduct has not been observed in full-length DNA.12, 13 The
nature of these adducts is important for a number of reasons, the most important one
being to understand the DNA repair mechanism in terms of how excision repair proteins
recognize lesions.14, 15
Figure 1. Structure of cisplatin (left) and steps in cisplatin hydrolysis (right, top & bottom)
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Goal of current study: Effect of Strand Orientation
As mentioned earlier, the most commonly seen cisplatin-DNA adduct is the
bifunctional intrastrand adduct GpG, which is followed by ApG. However, an isomeric
GpA adduct has never been observed in DNA. Experimental studies on a DNA sequence
containing the trimer 5’ApGpA 3’ have shown that after platination of the central guanine,
ring-closure to form a bifunctional adduct favors formation of ApG adducts (Fig 3).16
Thus there is a preference for closure from the 3’ end to the 5’ end. Previous attempts to
explain this preference suggested that the N7 of the adenine to the 5’ end was at a shorter
distance (3 Å) compared to that at the 3’ end (5 Å). However this explanation failed to
take into account any local distortion upon monofunctional binding.1 In addition, 1,3-
intrastrand crosslinks are relatively common binding motifs, suggesting that a reasoning
based on Pt-N distance alone is not sufficient. This project aims to understand the
structural details of this preference.
Figure 2. Types of cisplatin adducts28
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Methods
Computational Details:
All calculations were performed using the quantum mechanical package Jaguar
5.517, 22 based on Density Functional Theory.18, 19 The basis sets used were B3LYP/6-
31G**/LACVP + B3LYP/cc-pVTZ(-f)/LACV3P.23, 24, 25, 26 All energies were ZPE
(unscaled freq.) corrected and entropy terms at T=298.15K were added. Solvation
energies were computed using a continuum solvation model using water as the solvent.27
I. Modeling of Platinated ApG and GpA nucleotides
Initial attempts were made to model the platinated bases as part of larger
nucleotide chains such as trinucleotides (AGA, GAG), heptanucleotides (CCA*G*ACC,
CCAG*A*CC) and double-stranded pentanucleotides. However, the larger structures
were not stable in the gas phase and geometry optimizations either did not converge at all
or gave extremely distorted structures. The most reasonable structures were dinucleotides
BpB and pBpBp (B=base, p=phosphate). The rest of the project focuses on comparisons
among BpB-type structures.
II. Modeling of Platinated ApG and GpA dinucleotides
ApG and GpA dinucleotides (henceforth referred to as AG and GA, respectively)
with cisplatin bifunctionally bound to their N7 atoms (Fig 4) were geometry optimized as
Figure 3.1 Bifunctional binding in AGA trimer
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described above. The initial geometry guess was obtained by modifying cisplatin-bound
DNA structures taken from the Protein Data Bank (PDB IDs: 1KSB20, 1AIO31, 1A8432).
Both optimized structures starting from 1SKB were found to be lowest in energy, and
were used for further analyses.
Results and discussion
The thermodynamic data for AG and GA pairs from all starting PDB structures
follow experimental predictions, with AG being lower in energy than GA. The lowest
energy pair staring from 1SKB was used for further analysis. The AG adduct is lower in
energy than GA by around 7 kcal/mol, of which around 3 kcal/mol is attributed to
electronic energy difference, and around 3.5 kcal/mol originates from solvation energy
difference. (Table 1).
Table 1: Summary of thermodynamic data for GA and AG systems.
Type ?E(SP
) (eV)
ZPE
0 K
(Kcal/
mol)
?H
(eV)
Entropy
298.15
K
(cal/mol
K)
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298.15
k
(Kcal/
mol)
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(eV)
?G
(Solv)
(kcal/
mol)
?G(So
l) (eV)
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mol)
GA  -
74492.
634
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74476.
928
246.76 73.57 -
74480.
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-
186.57
-
74488.
209
AG  -
74492.
361.62 -
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248.60 74.12 -
74480.
-
190.11
-
74488.
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767 085 300 544
GA –
AG
kcal/
mol
3.07 0.57 3.64 -1.84 -0.55 4.18 3.54 7.72 7.72
Kinetically, GA has a higher activation barrier than AG, even though the
monofunctional and transition state structures have lower energy for GA compared to AG
(Fig 5). Thus, there is both a thermodynamic and kinetic preference for AG over GA.
Figure 4. Optimized geometries of Platinated ApG and GpA
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Figure 5. Reaction energy profile for AG and GA. Even though absolute energies for AG are
higher than GA in monofunctional and transition state structures, the activation energy for
AG (14.8 kcal/mol) is lower than GA (16.2 kcal/mol) by 1.4 kcal/mol.
Note: The bifunctional products shown above were modeled using one explicit water molecule
as the leaving group, to keep monofunctional, transition state and bifunctional structures
mass-balanced.
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Tracing the energy difference between AG and GA ? Energy decomposition studies
Note: In the following sections [Pt] indicates the platinumdiammine species Pt(NH3)22+
The electronic energy difference of 3 kcal/mol is important, as it indicates an
intrinsic preference for AG over GA that we must understand in greater detail. To derive
such a deep conceptual understanding, we devised an energy decomposition protocol by
systematically removing structural components of the model and comparing the energies
of the smaller fragments. This “divide and conquer” approach is designed to reveal which
portion of the molecule is responsible for the energy difference. In this case, the energy
decomposition consisted of the following steps, starting from fully optimized dinucleotides
(Fig 6):
• Compare energies of base + [Pt], i.e. removing sugar-phosphate backbones
• Compare energies of sugar-phosphate backbones
• Compare energies of dinucleotides without [Pt]
– Removing one base
– Removing one base + sugar
– Removing base + sugar + phosphate
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Hypothesis 1: H-bond between O6 of 3? Guanine and NH3 ligand of cisplatin
A strong hydrogen bond is present between the O6 of the 3’ guanine and one of
the NH3 ligands of cisplatin. This hydrogen bond is absent in the GA dinucleotide due to
the right-handedness of the DNA helix (Figure 6a). If this bond is responsible for the
observed energy difference, it should be maintained in the fragment containing [Pt] with
the two bases after removing the sugar-phosphate backbone. However, no energy
difference is observed between the two structures, suggesting that the hydrogen bond does
not have a differentiating contribution. This finding is in good agreement with an
GA
AG
0.37 kcal 0.81 kcal
a. Platinated bases b. Sugar-Phosphate backbone c. Dinucleotide conformations
2.31 kcal
Figure 6. Comparison of fragments
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experimental observation where the [Pt] unit was replaced by N,N'-dimethylpiperazine,
which lacks NH groups, and was found to have the same conformation of the dinucleotide
as the platinated model, suggesting that the hydrogen bonding between the O6 of guanine
and the amine of cisplatin was not important.21
The sugar-phosphate backbone fragments are structurally almost superimposable
and are only 0.8 kcal/mol apart (Figure 6b). Thus the possibility of backbone distortion
leading to the energy difference can be ruled out.
The dinucleotide fragments of AG and GA after removing [Pt] differ in energy by
2.3 kcal/mol (Figure 6c). This means that most of the overall energy difference comes
from the difference in these 2 structures. Since the backbone contribution is small, as seen
from Figure 6b, the major contribution to the energy difference is the arrangement of the
bases relative to the sugar-phosphate backbone.
The results lead to the conclusion that the [Pt] fragment has no direct electronic
contribution to the observed energy difference in the final geometries. This is a surprising
result and may suggest that there is nothing “special” about cisplatin binding, and the
physical phenomenon of interest is generally valid for bifunctional substrate binding.
Hypothesis 2: Glycosidic bond length flexibility
As the overall energy difference can be reproduced by the fragments shown in
Figure 6c, the non-platinated dinucleotides AG and GA were further analyzed and
fragmented.
  The glycosidic bond of the 5’ base was found to be elongated to 1.501Å and
1.503Å for ApG and GpA respectively, compared to approximately 1.48 Å in natural
DNA. Therefore smaller models were made to test the hypothesis that the energy
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difference was due to the fact that adenine was intrinsically more flexible than guanine,
thus leading to a more stable structure even with an elongated glycosidic bond. This,
however, is not the case, since the energy difference is maintained when the glycosidic
bond lengths are changed. Thus the bond length has only a negligible contribution.
Since the two dinucleotides are almost perfectly superimposable, the next step was
to further fragment the structures by removing one base at a time, followed by the sugar-
phosphate backbone (Fig 7).
Isodesmic energy comparison
Energy comparison between adenine and guanine containing structures was carried
out by subtracting the difference between free adenine and guanine from the difference in
the two structures, thus keeping the comparison mass-balanced. The results are
summarized in Fig 8 below.
??
S Base
Phosphate
S Base
Figure 7. Successive removal of components
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The energy profile shown above leads to the following conclusions:
· The 3’ bases do not contribute to the energy difference since they are almost
identical.
· The 5’ bases can reproduce the energy difference between AG and GA
dinucleotides, and thus may be solely responsible for the overall energy
difference.
Hypothesis 3: 3?-endo sugar pucker more favorable for adenine
The 5’ bases undergo a conformational transformation of the sugar pucker upon
platinum binding from 2’-endo to 3’-endo. This enables the 5’ base to bind to the platinum
below it, by making it axial. The 3’ sugar may or may not change its pucker upon
platination, and appears to contribute to bifunctional binding by bending upwards towards
the platinum above it.
To test this hypothesis, further fragmentation was carried out, successively
reducing the model to a nucleotide and finally to a nucleoside. The results are somewhat
ambiguous and some aspects of the relative energies do not match the profile above.
Figure 8. Comparison of fragments after removing one base
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Further work is currently ongoing. One consistent feature is the energy difference of
approximately 2.5 kcal/mol between the 5’ sugars with 3’-endo pucker attached to
guanine and adenine.
Thus, the conclusion so far is that the differences in formation of AG and GA are
due to intrinsic preferences for a particular type of sugar puckering and are not directly the
result of the cisplatin unit itself, as evident from Figures 6 and 8.
Future work
Some of the inconsistencies in the data must be resolved. Diverse fragmentation
strategies are being pursued, in addition to varying technical parameters to ensure that the
computed results are not numerical artifacts. Another possible approach being considered
is to simplify dinucleotides to purines and sequentially add the functional group to trace
the energy contributions. Finally, the transition state for bifunctional closure will be
reoptimized by modeling the sugar pucker switch, as we had not paid enough attention to
this feature in our initial approach.
A detailed kinetic profile will be mapped by considering all possibilities including
sugar pucker switching before and after the platination step. Since it still holds that the
observed preference for one conformer over another has little to do with the actual species
forming the adducts and more to do with which distortions are actually allowed
energetically, it seems reasonable to propose a generic mechanism for formation of these
bifunctional adducts via sugar pucker switching, and use other bifunctionally binding
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species to validate these claims. Some examples could include oxaliplatin (Fig 9) and
melphalan, a nitrogen mustard (Fig 10).
Figure 9. GpG bifunctional adduct by Oxaliplatin (DACH) 29
Figure 10. Schematic of bifunctional binding by Nitrogen Mustards
http://www.ovc.uoguelph.ca/BioMed/Courses/Public/Pharmacology/pharmsite/98-409/Cancer/Anticancer_drugs1.html#Nitrog_Must
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